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Summary We have evaluated the RNA-directed cytotoxicity of 5-fluorouracil (5-FU) in human colonic
carcinoma cells. The mode of action of 5-FU and its effects on human pre-rRNA processing were then
examined. From these data, possible reasons why the disruption of pre-rRNA maturation could induce
cytotoxic effects are considered. The results imply that inhibition of thymidylate synthase is not the sole
primary cytotoxic lesion in this cell line. First, exogenous thymidine (dTHd) enchanced cytotoxicity. Second,
addition of dThd to the cells was found to enhance incorporation of 5-FU into total cellular RNA. Third,
5-FU disrupted rRNA processing by a different mechanism from actinomycin D and methotrexate (MTX),
suggesting that the inhibition was not just a consequence of cell death. Finally, the addition of dThd was
found to enhance the disruption of rRNA processing consistent with an increase in concentration of 5-FU.
These data are discussed in the light of literature reports and their potential for optimising 5-FU protocols.
The concept of 5-FU cytotoxicity mediated solely through
the inhibition of thymidylate synthase has been widely
accepted in drug therapy manuals (Knobf et al., 1981; Port-
lock & Goffinet, 1986) and textbooks (Stryer, 1988)., How-
ever, contradictory reports on its mode of action have
appeared in the recent scientific literature. For example,
independent inhibition of thymidylate synthase by a different
drug (CB3717) does not enhance the toxicity of 5-FU (Cant-
well & Harris, 1988) and CB3717 is similarly ineffective in
the clinical management of colorectal cancer (Harding et al.,
1988). The drug is however clinically effective in certain other
tumours (Cantwell et al., 1988).
Despite interest in novel targeting systems, there is a
significant interest in the use of modulating compounds to
improve the therapeutic indexes of drugs currently marketed.
Four theoretical classes of such modulating compounds in-
clude: ones that selectively induce normal cell arrest, ones
that induce metabolic canalisation, selective protection and
inhibition of repair mechanisms (Spiegelman et al., 1980a, b).
As the cytotoxicity of 5-FU has been attributed, in part, to
its incorporation into RNA molecules, concomitant therapy
with modulating compounds that enhance the incorporation
of 5-FU into RNA could increase its anti-tumour activity
(Kufe & Egan, 1981; Spiegelman et al., 1980a, b). The meta-
bolic interactions of compounds advocated for clinical use
include thymidine (dThd), methotrexate (MTX) and N-(phos-
phonacetyl)-L-aspartate (PALA) (Figure 1).
Pre-treatment with dThd was predicted to prevent 5-FU
degradation by saturating the relevant enzymes. This nucleo-
side led to an accumulation of thymidine triphosphate
(dTTP) which induced feedback inhibition of ribonucleotide
reductase, the result of which was selective arrest of normal
cells (Spiegelman et al., 1980b). Resulting high levels ofdTTP
were believed to repress the anabolic conversion of 5-FU into
its deoxy-derivatives, thus preserving it for entry into RNA
(Spiegelman et al., 1980a).
Treatment of cells with MTX, an inhibitor of dihydro-
folate reductase, could result in depletion of reduced folate
cofactors required for de novo pyrimidine biosynthesis
(Fernandes et al., 1981). PALA, an inhibitor of aspartate
transcarbamylase, has been shown to induce market reduc-
tions in uracil nucleotide pools by inhibiting de novo
pyrimidine synthesis (Kufe & Egan, 1981). These inhibitors
also induce a reduction in the uracil nucleotide pools which
compete with 5-FU metabolites for incorporation into RNA.
Both MTX and PALA are believed to raise PRPP pools
which could be utilised in the activation pathways of 5-FU
(Heidelberger et al., 1983; Ardalan & Glazer, 1981).
Incorporation of 5-FU into RNA can, in principle, have
several consequences, of which the most significant is the
erroneous processing of rRNA precursors (Greenhalgh &
Parish, 1989). We therefore used the accumulation of these
precursors as diagnostic for the consequences of incorpora-
tion of 5-FU into RNA. We exploited our previous technique
of using cDNA probes for measuring steady state concentra-
tions of the molecules as this eliminates systematic errors
arising from incorporation studies (5-FU and its adjuvants
necessarily affect pyrimidine nucleoside/nucleotide pools).
The transcriptional unit, the probes involved and nomen-
clature used in the Discussion are summarised in Figure 2.
In order to simplify the biological problem, we have used
defined cell culture conditions to elucidate the effect of these
modulating compounds on the cytotoxicity of 5-FU and
observed the changes of concomitant therapy on rRNA pro-
cessing.
Materials and methods
Drugs and chemicals
The cell culture reagents were purchased from Gibco (Pais-
ley, UK) and other antibodies, drugs and chemicals were
obtained from Sigma Chemical Company (Poole, UK). a-32P-
dCTP, > 3,000 Ci mmol-', and 5-6-3H-fluorouracil, 12.9 Ci
mmol ', were supplied by New England Nuclear Research
Products (Boston, USA).
Cell culture
Human colonic tumour cell line HT-29 (Fogh & Trempe,
1975) was maintained at 37°C, 5% C02, 95% air in Dulbec-
co's modification of Eagle's minimal essential medium
supplemented with 10% (v/v) fetal calf serum (FCS), 0.3%
(v/v) NaHCO3, 1 mM sodium pyruvate and 50 mg ml-I gen-
tamycin. Sub-confluent stock cultures were passaged after
incubation with trypsin-EDTA and confirmed to be free of
mycoplasmas by staining with Hoechst 33258 stain (Chen,
1977). Viability was determined with trvn""n 'Green-
halgh & Parish, 1989).
Immunofluorescence
Cells were grown on glass cover slips, washed twice in PBS,
fixed in acetone at - 20°C for 5 min and dried. Sticky sites
were blocked by incubation for 30min with 10% (v/v) goat
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Figure 1 Metabolic interaction between MTX, PALA and 5-FU
metabolism. Enzymatic steps: 1, asparate transcarbamylase; 2,
pyrimidine phosphoribosyl transferase; 3, thymidylate synthase;
4, dihydrofolate reductase. PRPP, 5-phosphoribosylpyrophos-
phate; THF, tetrahydrofolate; DHF, dihydrofolate.
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Figure 2 rDNA transcriptional unit showing the origins of the
rDNA probes used in this work. NTS, non-transcribed spacers;
ETS, external transcribed spacer; ITSs, internal transcribed
spacers; 18S, 5.8S and 28S mature rRNA sequences. The charac-
ters above the bar represent start (S) and termination (T) sites for
transcription and processing sites 1-6. S, Xh, X, E and B (below
the bar) are restriction sites and below them are cloned rDNA
probes.
serum, 0.1 ml of the antinucleolar antibody was added and
incubated for 1 h. The slide was rinsed, washed three times
with PBS, dried and 50 tl of the FITC-conjugated second
antibody (1/50 dilution in PBS) was added and incubated for
1 h. The slide was washed with PBS, dried and mounted. The
cells were visualised under epifluorescence in a Leitz Dialux
20EB microscope, and photographed using a Leitz Vario-
Orthomat camera system with Ilford XPI 400 black and
white film uprated to 800 ASA.
RNA isolation
Nuclear and cytoplasmic RNAs were isolated from subcell-
ular fractions (Greenhalgh & Parish, 1989). Whole cellular
RNAs were extracted directly from the cells by the PAS-
TIPNS method and quantified by the orcinol reaction
(Parish, 1972).
filters followed standard methods (Maniatis et al., 1982). The
filter was pre-hybridised and then hybridised in fresh pre-
hydridisation buffer containing 6% (w/v) PEG 6000 and a
heat denatured 32P-labelled DNA probe prepared by the
hexamer labelling method (Feinberg & Vogelstein, 1983,
1984), at 42°C for 24 h. The filter was washed twice for
30 min in 0.2 x SSC, 0.1% (w/v) SDS at 42°C followed by a
30 min wash in 0.1 x SSC, 0.1% (w/v) SDS at 65°C and
exposed to X-ray film at - 70°C using a Du Pont Lightning
Plus intensifying screen.
Composite gel electrophoresis
Five mg RNA was fractionated by the method of Peacock
and Dingman (1968) using 1.5% (w/v) polyacrylamide/0.7%
(w/v) agarose composite electrophoresis gels. Following
electrophoresis, the gel was stained with ethidium bromide
and the RNA bands were visualised with u.v. light. Fluoro-
graphy was performed as described (Laskey & Mills, 1975),
and the films were exposed at -70°C before photographic
processing.
Estimation ofradioactivity in hydrolysed RNA
Radiolabelled RNA was completely hydrolysed to its con-
stituent mononucleotides by the method of Bock (1967). The
nucleic acids were precipitated with TCA in the presence of
carrier salmon sperm DNA, collected on Whatman G/FC
filter discs and washed extensively with TCA as described
(Maniatis et al., 1982). The radioactivity was determined by
liquid scintillation counting using a toluene based scintillant
(0.4% (w/v) PPO in toluene).
Results
Effect of5-FU on cell viability in combination therapy
The cytokinetic and biochemical modulation of 5-FU toxicity
by both thymidine (dThd) and methotrexate (MTX) have
been observed in the human colon carcinoma cell line HCT-8
(Matsuoka et al., 1986; Benz et al., 1984). These findings
were used as a guide to determine the comparable conditions
for HT-29 cells. The cells were incubated for 18 h in 0.5 mM
dThd and the effect of pre-treatment on 5-FU toxicity was
determined. Treatment with 0.5 mM dThd alone induced a
10% reduction in cell viability while incubation with
10.0 mM MTX induced a 60% reduction in viability when
compared to the untreated cells. Pre-treatment of the cells
with 0.5 mM dThd was believed to be relatively non-toxic.
Pre-treatment of the cells with 0.5 mM dThd concurrent with
10 and 1I00 M 5-FU were found to significantly reduce cell
viability when compared with their respective controls.
Effect ofdThd on incorporation of5-FU into total RNA
Control cells were incubated for 6 h in media supplemented
with non-cytotoxic concentrations (approximately 350 nM) of
radiolabelled 5-FU. Others were pre-incubated with dThd
before the addition of 5-FU. The results of two separate
experiments established that the incorporation of 5-FU into
total RNA was enhanced approximately 1.5-fold by the dThd
pre-treatment (Table I). The fact that the experiment
measured the incorporation of radiolabelled 5-FU into total
RNA molecules (rather than into contaminating DNA) was
established by the alkali-lability of the radioactivity.
Table I Effect of dThd on the incorporation of 5-FU into total
RNA
Blot hybridisation
Seven mg of RNA was fractionated by agarose gel electro-
phoresis using formaldehyde as a denaturant. The running
buffer contained 20 mM morpholinopropane-sulphonic acid,
5 mM NaOAc and 1 mM EDTA (pH 7.0); other details of
electrophoresis and subsequent transfer to nitrocellulose
Disintegrations min-I per pg RNA
Experiment Treatment Before NaOH After NaOH
1 5-FU 186.6 ± 9.7 4.0 ± 0.3
2 dThd/5-FU 284.1 ± 14.7 4.4± 0.6
3 5-FU 194.3 ± 21.9 4.4 ± 0.5
4 dThd/5-FU 329.3 ± 33.9 3.1 ± 0.4EFFECT OF 5-FU ON RNA PROCESSING 417
Effect of5-FU on nucleoli
Electron microscopy has revealed alterations in the morpho-
logy of nucleoli in cells after treatment with 5-FU (Stenram,
1969). Anti-nucleolar antibodies are commercially available
and are a means of non-destructively assaying cell mono-
layers for changes in nucleolar structure in situ. The effects
of 5-FU treatment upon nucleolar structures were studied
using such anti-nucleolar antibodies (Figure 3). Photographic
prints of the nucleolar and cell shapes were digitised and
their areas calculated. It was estimated that 5-FU induced an
increase of45% on nucleolar surface area whilst there was an
increase of 15% in cell size. These results were found to be
statistically (at the 5% level) different from the untreated
control cells.
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Processing ofpre-rRNA
As a preliminary experiment we established that 5-FU is
incorporated into pre-rRNA (Figure 4). 3H-labelled 5-FU
was incorporated into the 45S rRNA primary transcripts
after 20 min and the labelled mature rRNA species appeared
in the cytoplasm after 150 min. Thus, 5-FU-labelled pre-
rRNA molecules were processed over a similar time scale,
possibly by a similar pathway, to that of the uridine-labelled
rRNA precursors (data not shown).
Effects of adjuvant pre-treatment on the disruption of
RNA metabolism by 5-FU was assayed by the more versatile
method of blot hybridisation. The probes used were derived
from the rDNA transciptional unit (Figure 2) and were
found to be totally non homologous (Greenhalgh & Parish,
1989). The effects of MTX, actinomycin D and 5-FU, with
and without dThd pre-treatment, on pre-rRNA processing
were studied by blot-hydridisation analysis. After drug
treatment, the rRNAs were isolated from the nuclear and
cytoplasmic fractions of HT-29 cells, fractionated and blot-
hybridised with the probes B/XX and B/XE. Autoradio-
graphs (Figure 5) were scanned and quantified (Table II).
Treatment with 0.5 mM dThd did not significantly alter the
relative concentrations of pre- and mature rRNA. Treatment
with actinomycin D induced a reduction in the 45S rRNA
transcript and a subsequent increase in the relative concen-
tration of 28/32 S molecules. Treatment with 10 tM MTX
did not affect the relative concentrations of the rRNA
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Figure 3 Effect of 5-FU on nucleoli. Exponentially growing
HT-29 cells were treated with 1 mM 5-FU for 12 h. After treat-
ment, the nucleolar structures were detected by indirect
immunoflourescent staining using a human anti-nucleolar
antibody. Phase contrast and fluorescence pictures were taken of
untreated (I and 2) and drug treated cells (3 and 4).
b
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Figure 4 Incorporation of 3H-labelled 5-FU into the pre-rRNA
maturation pathway of HT-29 Cells. The growth medium was
supplemented with 5 mCi ml-' 3H-labelled 5-FU and after
various time intervals, the cells were harvested and washed in
PBS containing I mM non-radioactive uridine. RNA was isolated
from the nuclear and cytoplasmic fractions and fractionated by
polyacrylamide/agarose composite gel electrophoresis. The RNAs
were detected by either the u.v. visualisation of ethidium bromide
stained RNA (a) or by 3H-fluorography (b). Tracks on the gel
contained: RNA extracted after 10 min (1 and 2), 20 min (3 and
4), 40 min (5 and 6), 80min (7 and 8) and 150min (9 and 10).
The even and odd numbered lanes contain the cytoplasmic and
nuclear RNAs respectively. Track II contained unlabelled E. coli
RNA.
precursors when compared to the control cells. Hybridisation
with the 18S probe B/XE revealed that MTX treatment
induced a significant increase in the level of 18S rRNA
relative to the other precursors when compared to untreated
cells. Treatment with 5-FU induced several changes in
precursor rRNA molecules. The ETS probe revealed that as
the concentration of 5-FU increased there was a reduction in
the steady-state levels of the 45S primary transcript and a
relative increase in the 41S and 37S molecules. Hybridisation
with probe B/XE suggested a reduction in the steady-state
levels of41S, 20S and 18S rRNA. Adjuvant treatment appar-
ently increased the toxicity of 5-FU and induced changes in
the pre-rRNA molecules consistent with an increase in the
incorporation of 5-FU (Table II).
Discussion
The HT-29 cell line provided a reasonable model for the
purpose of the studies. The viabilities of cultured HT-29 cells
following exposure to 5-FU were in close agreement with
values obtained by the soft agar colony formation assays
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Figure 5 Effect of metabolic modulation on 5-FU induced dis-
ruption of rRNA processing. Autoradiographs of filters probed
with 32P-labelled B/XX (a and b) and the same filters probed with
32P-labelled B/XE (c and d). Filters a and c contained nuclear
RNA while filters b and d contained cytoplasmic RNA. Lane I
contains RNA derived from cells after incubation in media sup-
plemented with 4fg ml' actinomycin D for 30 min before ex-
traction. RNA from untreated cells (lane 2), RNA from cells
treated for 18 h wth 10 jAM MTX (3). RNA from cells treated for
18 h with 0.5 jAM dThd (4), RNA from cells treated for 6 h with
100 jAM and 0.5 mM 5-FU (5 and 7) and RNA from cells pre-
treated for 18 h with 0.5 mM dThd where 100 jAM 5-FU was
added for the last 6 h (6).
(Cohen & Glazer, 1985; Kane et al., 1987). Results from this
study also suggest that cytotoxicity of 5-FU was both con-
centration and time dependent, consistent with published
results (Link et al., 1988; Kufe et al., 1981). The clinical
aspects are discussed by Bruno et al. (1981).
We draw three main conclusions from the present studies.
First the experiments confirm that the cytotoxic action of
5-FU in the colonic tumour cell line involves the conse-
quences of its incorporation into RNA. Analysis of the
dTHd/5-FU combinations revealed that an 18 h exposure to
1 mM dThd alone was cytotoxic. In contrast, 0.5 mM dThd
was found to be a satisfactory non-toxic dose which could be
used to modulate the toxicity of 5-FU. When used in com-
bination with 10 and 100 j.M 5-FU, the relative cytotoxicities
were enhanced approximately 2-fold in comparison to 5-FU
alone, in agreement with observations on HCT-8 cells (Benz
et al., 1984) and leukaemia cells (Keniry et al., 1987). If the
cytotoxic lesion involved thymidylate synthase, pre-treatment
with dThd should have protected the cells from a 'thymine-
less' death (Rueckart & Mueller, 1960). Pre-treatment with
dThd not only increased the relative incorporation of 3H-
Table II Quantification ofthe autoradiographs presented in Figure5a
and c
Concentration ofspecies (% oftotal)
Track
no. 45S 41S 37S 32S 28S
Probe B/XX (a)
1 30.5 3.5 2.5 38.0 25.5
2 40.5 8.5 4.5 28.0 18.5
3 39.0 7.5 2.5 32.5 18.5
4 40.0 6.0 6.0 27.0 21.0
5 30.0 11.0 10.0 24.0 25.0
6 28.0 11.5 13.0 25.5 22.0
7 25.0 13.0 13.0 25.0 24.0
Probe B/XE (c)
45S 4JS 32S 28S 20S 18S
1 2.5 0.5 4.5 2.0 4.0 86.5
2 15.0 5.0 11.0 4.5 3.5 61.0
3 4.5 1.5 3.5 2.0 2.0 86.5
4 15.0 5.0 10.0 6.5 2.0 61.5
5 15.0 ND 18.0 8.0 ND 59.0
6 22.0 ND 18.0 8.0 ND 52.0
7 21.5 ND 27.5 12.0 ND 38.5
ND, not detectable.
labelled 5-FU into RNA metabolities (Table I), but also
enhanced the cytotoxic effect of 5-FU. The results were
consistent with the hypothesis that incorporation of 5-FU
into RNA is the mechanisms of 5-FU cytotoxicity (Major et
al., 1982).
Second, we are able to reach conclusions about the nature
of the disruption to RNA metabolism that is produced by
incorporation of 5-FU. Strictly these conclusions are only
valid for HT-29 cells but we believe they apply to other cases
of RNA-mediated 5-FU toxicity. The identification of rRNA
as the most sensitive class of RNA is supported by effects on
nucleoli, previously examined by electron microscopy of rat
liver after 5-FU treatment (Stenram, 1966, 1969). Nucleoli
are sites of rRNA processing as well as transcription (Had-
jiolov, 1985) and increase in nucleolar size may reflect
accumulation of misprocessed ribosome precursors (Glazer &
Legraverend, 1980). These data agree with the observations
of Takimoto et al. (1986, 1987) who found a significant
correlation between levels of 5-FU in newly synthesised RNA
and cytotoxicity. A similar relationship was demonstrated in
human breast carcinoma cell lines (Kufe & Major, 1981;
Major et al., 1982) and in patients suffering from breast
cancer (Ardalan & Glazer, 1981). MTX was used as a control
to show that misprocessing of pre-rRNA is not a general
feature of the death of cells and the data on actinomycin D
established that the misprocessed rRNA precursors are a
specific consequence of 5-FU incorporation and not as
general consequence of transcriptional inhibition. The unre-
solved issue is the reason why misprocessed molecules repre-
sent some kind of lethal synthesis.
Third, we point to a chemical pathological consequence of
the work. Since rRNA processing appears to be a major site
of action for 5-FU, rapid analysis of misprocessing by blot-
hybridisation of RNA isolated from tumour biopsies may
allow prediction of the optimal chemotherapeutic regime to
maximise tumour regression in individual patients.
D.A.G. was an SERC Research Student.
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